FDA expands use of Xalkori to treat rare form of advanced non-small ...
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration ...
Crizotinib for Advanced Non-Small Cell Lung Cancer - NCI
Jun 1, 2013 · A summary of results from an international phase III clinical trial that compared crizotinib versus chemotherapy in previously treated patients with advanced lung cancer whose tumors have …
Plain language summary: 5-year results from the CROWN study of ...
Oct 3, 2024 · In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who …
Crizotinib Not Beneficial in Resected Early ALK+NSCLC - Medscape
Sep 10, 2025 · Previously demonstrated survival benefits of crizotinib (Xalkori, Pfizer Inc.) as an adjuvant treatment for advanced ALK-positive non-small cell lung cancer (ALK+NSCLC) did not …
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK ...
May 31, 2024 · XALKORI is a tyrosine kinase inhibitor (TKI) indicated for the treatment of patients with metastatic NSCLC whose tumors are ALK- or ROS1-positive as detected by an FDA-approved test.
How effective is Xalkori? - Drugs.com
Feb 22, 2022 · Xalkori oral treatment helped to slow or shrink the growth of lung cancer tumors for 10.9 months in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) and for 18.3 …
XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment
Learn about Rx XALKORI® (crizotinib) for treatment of ALK+ or ROS1+ non-small cell lung cancer that has spread to other parts of the body. See risks & benefits.
What Is Xalkori for Lung Cancer? Are There Alternatives? - GoodRx
Jul 7, 2022 · Xalkori (crizotinib) is a targeted therapy medication used to treat certain types of non-small cell lung cancer (NSCLC). Xalkori treats lung cancer by blocking cancer-causing proteins made from …
Crizotinib (Xalkori) treats Lung Cancer | ChemoExperts
Treatment Name: Crizotinib (Xalkori®) Crizotinib (Xalkori®) is a Targeted Therapy for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does crizotinib work? Crizotinib is designed to bind to …
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
Jul 10, 2024 · The drug lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with advanced non-small cell lung cancer (NSCLC) that has changes in the ALK gene, …